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PathogenesisAbstract Human glioma is a highly fatal tumor with a signiﬁcant feature of immune suppression.
The functions of PD-L1 refer to co-simulation and immune regulation. To investigate expression
and functional activity of PD-L1 in human glioma cell in vivo and in vitro. Expressions of PD-
L1mRNA and protein in the human glioma cell line were analyzed with quantitative RT-PCR
and ﬂow cytometer; and then expression of PD-L1 in tissue specimens of 10 glioma patients was
treated with immunohistochemical analysis; glioma cell and allogeneic CD4+ and CD8+ T cells
were co-cultured, and cytokine IFN-c, IL-2 and IL-10 in cultured supernatant ﬂuid were deter-
mined with ELISA; upon blocking the interaction between glioma cell and the immune cell with
PD-L1 monoclonal antibody (5H1), surface markers on immune cells were analyzed using ﬂow
cytometer. All human glioma cell lines constitutively expressed PD-L1, and IFN-c induced glioma
cell to highly express PD-L1. It was shown through immunohistochemical analysis that glioma
specimen expressed PD-L1, while expression of PD-L1 was not observed in normal tissue and nor-
mal human brain near the tumor location. The release of IFN-c and IL-2 was inhibited, while IL-10
was increased slightly. Glioma cell may escape from immune recognition and injury with the help of
PD-L1, which is a signiﬁcant pathogenic mechanism of glioma.
ª 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glioma is known as glioblastoma and also neuroepithelial
tumors or neuroectodermal tumors for it occurs in neuroecto-
dermal regions. More and more evidence shows that the body
produces tumor-speciﬁc T cell-mediated immunity. However,
tumor-speciﬁc immune response is not sufﬁcient to eradicate
the neoplasm. Antigen-induced T cell activation and prolifera-
tion is regulated by the positive and negative costimulatory
receptor of the immunoglobulin superfamily (Mavilio and), http://
2 Y. Lou et al.Lugli, 2013). Glioma is a highly lethal cancer, and it is also a
typical tumor that can inhibit the effective anti-tumor immune
response (Walker et al., 2002; Ashraf et al., 2013). However, its
pathogenesis remains unclear.
PD-L1, the homolog of B7.1/2 (CD80/86), shows the ability
to co-stimulate molecules and regulate the immune system
(Joshua et al., 2013; Butte et al., 2007). It is expressed in APCs
and induced in the lymphoid and non-lymphoid peripheral tis-
sues to make the outer periphery of PD-L1 for the regulation
of activated T cells. IFN-c is an effective cytokine for up-
regulation of PD-L1, as IFN-c response element in the pro-
moter region of PD-L1. The expression of B7-DC (PD-L,
another PD-1 ligand) is substantially conﬁned to the medullary
DCs and macrophages, not in peripheral tissues or wide
expression in many cell types. Therefore the effect of inhibition
of peripheral T cell-mediated immunity is less.
The immune system inspects and removes mutative cells,
which are immune surveillance functions. Accordingly, the
tumor cells may change phenotype to escape the attack of
the immune response. Studies have shown that manipulation
of the tumor microenvironment PD-L1/PD-1 molecule path-
way and inducing expression of PD-L1 are associated with
the immune suppression of the tumor, thereby allowing tumor
progression and metastasis. PD-L1/PD-1 molecular pathway is
the main mechanism of tumor immune escape, for the follow-
ing reasons: First and most importantly, this approach is
involved in the immune response, especially in the negative
regulation of tumor origin and growth of the peripheral tis-
sues; Secondly, the up-regulation of B7-H1 in the tumor
microenvironment has also up-regulated the PD-1 in activated
tumor inﬁltrating T cells, which may start a vicious suppressive
loop; third, the pathway through a two-way signal interleaves
contact innate and acquired immune regulation. These factors
make the PD-1/B7-H1 molecular pathways that control the
immune response in cancer and its progression play a central
role. That is, the molecular axis of PD-L1/PD-1 that is con-
trolled by the tumor led ‘‘good genes’’ to worse (Pardoll,
2012; Butt et al., 2015; Batool et al., 2015).
In the present study, we show that the outer glioma cells
in vivo have a high expression of PD-L1 and PD-L1 expressed
by glioma cells reduces its immunogenicity in vitro. Thus, PD-
L1 is a new mediator with an immunosuppressive effect in
human gliomas.
2. Materials and methods
(1) Cell culture. Human malignant glioma cell lines LN-229,
U251MG and LN-308 were purchased from the Wuhan
University typical species preservation centers, these
cells are cultured according to the literature methods
(Wiendl et al., 2002).
(2) Immunohistochemistry. Tumor specimens including 9
glioblastoma (WHO grade IV) and a mixed glioma
(WHO III, female, n= 6, age range, 30–82 years old;
males n= 4, age range 60–71 years old) were obtained
from the operation of inpatient neurosurgery of our hos-
pital. A normal brain tissue and normal brain tissue
adjacent to tumor cells were used as control tissue.
Immunohistochemistry was in accordance with the liter-
ature (Wiendl et al., 2002). Frozen tissues were cut
(20 lm) and ﬁxed in acetone, using PD-L1 antibodyPlease cite this article in press as: Lou, Y. et al., Function of PD-L1 in antitumor
dx.doi.org/10.1016/j.sjbs.2015.06.025(5H1) or isotype control antibody staining. The reaction
product was observed with streptavidin-biotin staining
(Shenzhen Nano Biotechnology Co., Ltd.). The percent-
ages of positive staining of glioma cells as <25%, 25–
50%, 50–75%, and >75% were quantitated.
(3) PBMCs. Puriﬁed lymphocytes and DCs. PBMCs were
isolated from the peripheral blood of normal healthy
people (Wiendl et al., 2002). Separated by MACS
CD4+ and CD+ T cells (Miltenyi Biotec, Bergisch
Gladbach, Germany). Co-culture experiments were in
accordance with the literature (Wiendl et al., 2002).
Using ELISA (BD PharMingen) to detect cytokines that
released into the supernatant (human IFN-c, IL-2 and
IL-10). The surface molecular markers of activated T
cells were analyzed by ﬂow cytometry. Mononuclear
cells were obtained in RPMI1640 containing 10% fetal
bovine serum with 1 h adhesion at 37 C and cytokine
GM-CSF (100 ng/ml, Leukomax; Sandoz, Basel,
Switzerland) and IL-4 (40 ng/ml; PeproTech, Inc.,
Offenbach, Germany), after 6 days of culture these cells
display an immature DC phenotype (CD14 and CD1a+
and HLA-DRlow, CD86low, CD80low/and CD83).
Maturation was induced by LPS (5 lg/ml, S. typhi;
Sigma L-7261) or TNF-a (PeproTech EC Ltd
200 units/ml). Mature DC HLA-DR expression and
co-stimulatory molecules (CD86 and CD80).
(4) Flow cytometry analysis. The immune cell surface mark-
ers were analyzed by CellQuest software (FACSCalibur
cytometer; Becton Dickinson, Heidelberg, Germany).
Count 10,000 events/antigen. The histogram was
obtained by calculating SFI.
(5) Co-culture experiments. Co-culture experiments were
performed according to the literature (Wiendl et al.,
2003). 5 · 104 glioma cells/well in 48-well culture plate
types (Costar, Bodenheim, Germany), cultured with or
without containing IFN-c (500 units/ml) for 24 h to
induce the expression of MHC-II PD -L1. The cells were
washed with PBS, and 0.5 * 106 freshly puriﬁed T cell
types (CD4+ and CD8+) were added to them. Then
the cells were co-cultured in RPMI1640. To describe
glioma – correlation functions of immune cell interac-
tions anti PD-L1 mAb (5H1) or a control antibody
was added in accordance with the respective predeter-
mined time or design. For all blocking experiments,
co-culture was added in anti-PD-L1 (5H1). To detect
the production of cytokines (human IFN-c, IL-2 and
IL-10), the supernatant was collected and analyzed by
ELISA (BD PharMingen).
(6) RNA extraction, cDNA synthesis and quantitative
RT-PCR. Total RNA was extracted using Trizol
(Invitrogen) according to the reagents operating instruc-
tions. RevertAid First Strand cDNA Synthesis Kit (MBI
Fermentas, St. Leon-Rot, Germany) was used for
cDNA synthesis and PCR ampliﬁcation and DyNAmo
Flash SYBR Green qPCR kit (Finnzymes Oy, Espoo,
Finland) for Real-time PCR. Expression levels were cal-
culated and normalized 18s rRNA. Primers 18srRNA
and PD-L1 are shown in Table 1.
(7) Statistical analysis. Data processing using SPSS 11.0
software package, data were described in x sE and
t-test was used to compare the differences between two
groups. P< 0.05 indicates signiﬁcant difference.immunity of glioma cells. Saudi Journal of Biological Sciences (2016), http://
Table 1 Primers of 28srRNA and PD-L1.
Gene Sequence (50–30)
18s-for CGGCTACCACATCCAAGGAA
18s-rev GCTGGAATTACCGCGGCT
PD-L1-for TCAATGCCCCATACAACAAA
PD-L1-rev TGCTTGTCCAGATGACTTCG
Function of PD-L1 in antitumor immunity of glioma cells 33. Results
The expression of PD-L1 in human glioma cell lines. Expressed
by the following by to detect. The PD-L mRNA expression of
three kinds of human glioma cell lines was detected by qRT-
PCR with or without the presence of IFN-c (500 units/ml,
48 h). All glioma cell lines consisted of low-expressing PD-L1
mRNA. In the presence of IFN-c, PD-L1 transcription (LN-
308) increased 4.2-fold (Fig. 1A). Compared with IFN-c,
TNF-a has no effects on the expression of PD-L1mRNA (data
not shown). Flow cytometric analysis of glioma cell lines
revealed that the entire surface thereof has a composition for-Figure 1A Using real-time quantitative RT-PCR to detect the PD-L
without IFN-c (500 units/ml).
Figure 1B Using ﬂow cytometry to analyze the PD-L1 protein expre
(500 units/ml).
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L1 expression enhanced from 3.6 times to 17.2 times with SFI
ratio (LN-229) (Fig. 1B).
1. PD-L1 expression of Gliomas in vivo. By immunohisto-
chemical staining, PD-L1 expressed in nine glioblastoma
(WHOIV) and a mixed glioma. More than 50% of the tumor
cells in glioblastoma tumors express PD-L1 (50–90%), and
PD-L1 positive cells dispersed in the specimen uniformly, while
in the adjacent normal tissue in the tumor or normal sample,
no expression of PD-L1 has been found (Fig. 2).
2. The functional correlation analysis of PD-L1 expression.
Production of T cell cytokines and the inhibition of the expres-
sion of activation markers. To study the function and meaning
of the PD-L1 expression derived from glioma cells, we cultured
and puriﬁed the helper T cells with or without PD-L1 antibody
using co-culture experiments. In addition to PD-L1, LN-229
glioma cells show a high expression of HLA-I composition for-
mula and HLA-DR antigen. When the puriﬁed CD4+ T cells
and LN-229 glioma cells were co-cultured, HLA-DR antigens
and CD4+ T cell T cell receptors interacted, leading to the
activation of T cells and the production of cytokines. Accord-
ingly, HLA-I antigen of CD8+ T cells and glioma cells inter-
act, leading to T cell activation. Cytokines (IFN-c, IL-2 and1 mRNA expression of 48 h cultured human glioma cells with or
ssion of 48 h cultured human glioma cells with or without IFN-c
immunity of glioma cells. Saudi Journal of Biological Sciences (2016), http://
Figure 2 The expression of brain tumor samples of PD-L1 analyzed by immunohistochemistry. (A) and (B) glioma; Normal brain tissue (C).
4 Y. Lou et al.IL-10) in the culture supernatants were detected by ELISA at
predetermined release time points. Fresh not activated puriﬁed
CD4+ and CD8+ T cells were co-cultured with glioma for 24
and 48 h. By adding anti-PD-L1 antibody, cytokines increased
in co-culture supernatant (IFN-c: CD4+ T cells 310 ± 12.9%,
P= 0.017; CD8+ T cells: 159 ± 8.0%, P= 0.270; IL-2:
CD4+ 176 ± 15.3%, P= 0.011; CD8+ 146 ± 5.7%,
P= 0.338; Table 2). PD-L1 took the most signiﬁcant inhibi-
tion on the production of IFN-c and IL-2 by CD4+ T cells.
CD8+ T cells were also inhibited, but the production of
cytokines did not reach statistically signiﬁcant levels. The pro-
duction of IL-10 varies between different donors. Generally,
blockaded PD-L1 will increase the level of IL-10, but this
effect is not signiﬁcant (CD4+ T cells: 128 ± 5.3%,
P= 0.096; CD8+ T cells: 119.2 ± 11.5%, P= 0.201)
(Table 2).
4. Discussion
A variety of immune evasion strategies prompt cancer progres-
sion. Glioma is a typical suppressed tumor with anti-tumor
immune response, and the factors include TGF-b, and IL-10
release, CD95L, CD70, or HLA-G (Wiendl et al., 2002)
expression. Glioma immunotherapeutic strategies eliminate
immunosuppressive mechanisms or strengthen the anti-tumorTable 2 Functional consequences of PD-L1 expression for
cytokine expression.
Cytokine Isotype Ab HLA-I Ab PD-L1 Ab
IFN-c CD4+ T 100 54 ± 7** 310 ± 12.9*
CD8+ T 100 61 ± 5* 159 ± 8
IL-2 CD4+ T 100 37 ± 4** 208 ± 15.3*
CD8+ T 100 92 ± 6 146 ± 5.7
IL-10 CD4+ T 100 121 ± 10 128 ± 5.3
CD8+ T 100 115 ± 8 120 ± 11.5
LN-229 glioma cells with the same kind of immune cells and CD4+
and CD8+ T cells were co-cultured for 48 h with the same type of
antibodies, HLA-I antibody and PD-L1 antibody (5H1), and reg-
ulation of PD-L1 on cytokine IFN-c, IL-2 and IL-10 was evalu-
ated. Cytokine levels stimulated by the same antibodies were taken
as 100, compared with their relative levels of cytokines.
** Indicates P< 0.01.
* Indicates P< 0.05.
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we demonstrate that PD-L1, one of the B7 family of co-
stimulatory molecules, composed the formulation of glioma
lines (Fig. 1A). Immunohistochemical analysis showed that
PD-L1 was expressed in brain tumor specimens, but did not
express near the site of the tumor and normal human brain tis-
sue (Fig. 2). In vitro co-culture experiments, we demonstrated
that PD-L1 signiﬁcantly impaired anti-tumor immune
response to T cell cytokine production (see Table 2).
Under physiological and non-inﬂammatory conditions,
PD-L1 is the main antigen presenting cell in the body, such
as the expression (Carter et al., 2002) of monocytes and
DCs. However, under inﬂammatory conditions, PD-L1 is no
longer limited to antigen presenting cells, it is also expressed
by other cells such as endothelial and muscle cells (Surhio
et al., 2014).
Our study provides evidence of PD-L1 expression in the
brain in vivo. All malignant gliomas express PD-L1, but it
was not expressed near the site of the tumor and normal
human brain tissue (Fig. 2). This is similar to the culture of
glioma cell lines in vitro (Fig. 1A). It remains unclear how
and when to express PD-L1’s by the glioma cells. In consis-
tence with the previous results, RNA and protein levels of
PD-L1 expression in glioma cells were signiﬁcantly upregu-
lated in inﬂammatory cytokines, such as IFN-c stimulation,
but there was no such effect in TNF-a (Fig. 1A).
PD-L1, expressed by glioma, is an anti-immune response
inhibitor. This has been proved by co-culture experiments
in vitro. With the presence of anti-PD-L1 antibody, the pro-
duction of IFN-c and IL-2 by CD4+ and CD8+ T cells were
signiﬁcantly strengthened, and IL-10 is only slightly raised.
Recent studies have shown that activated T cells stimulated
by PD-L1 lead to apoptosis (Dong et al., 2002), and the prolif-
eration of activated T cell and cytokine production will be
inhibited by the combination of PD-1 and PD-L1 (Freeman
et al., 2000; Carter et al., 2002). Recent studies also showed
that the expression of PD-L1 in DCs exert an intense immuno-
suppressive effect on the activation of T cells. Thus, PD-L1 is
an important molecule for induction and maintenance anergy
of T cell under physiological conditions, which is conducive to
the immune body from damage caused by excess immune
response under normal physiological conditions, and to
immunological tolerance to self-antigens (Brown et al., 2003;
Selenko-Gebauer et al., 2003). In addition to the interaction
between PD-1 and PD-L1, the inhibitory effect of PD-L1
can be mediated by other receptors (Naureen et al., 2014;immunity of glioma cells. Saudi Journal of Biological Sciences (2016), http://
Function of PD-L1 in antitumor immunity of glioma cells 5Kiyani et al., 2014; Khaskheli et al., 2015). Our results support
that PD-L1 plays a negative regulatory function on T cell acti-
vation on the whole. Glioma associated PD-L1 expression is a
mechanism of immune suppression of tumor escape immune
recognition and destruction in the CNS.
5. Conclusion
Glioma related inhibition of T cell in vivo by PD-L1 indicates
that this co-stimulation molecule inhibits the T cell growth and
cytokine production. Thus, PD-L1 glioma associated expres-
sion may affect the anti-immune response at the initial and sec-
ondary phase in vivo conditions. PD-L1 could inhibit T-cells
at the start and DC functions to interfere with the primary
anti-tumor immune response (Brown et al., 2003; Selenko-
Gebauer et al., 2003; Curiel et al., 2003). Moreover, PD-L1
can protect glioma cells from directly attacking the antigen-
speciﬁc cytotoxic T cells (Saﬁ et al., 2015). The present results
indicate that the effective blockage of the interaction between
PD-1 and immune effector cells can be used as a potential ther-
apeutic strategy for immunotherapy of glioma in vivo. It also
means that the blocking of the PD-1/PD-L1 pathway has a
potential value for immunotherapy of the glioma.
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